Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
NCT05060003 · Washington University School of Medicine · PHASE2 · terminated · last registry update 2024-02-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor made decision to terminate study.” | – | Registry record, Washington University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-27Results posted on the registry: National Cancer Institute (NCI), Olaparib + Durvalumab (NCT04538378)
- 2024-12-13Phase 3 first posted: National Cancer Institute (NCI), Ceralasertib + Durvalumab (NCT06732401)
- 2024-12-02Phase 3 first posted: BioNTech SE, Pumitamig + Atezolizumab (NCT06712355)
- 2024-10-17Phase 3 first posted: Bristol-Myers Squibb, BMS-986489 (Atigotatug+Nivolumab) + Atezolizumab (NCT06646276)
- 2024-10-17Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Trastuzumab (NCT04661150)
- 2024-10-09Phase 3 first posted: Alliance for Clinical Trials in Oncology, Cisplatin + Carboplatin (NCT06632327)
- 2024-10-01Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-8068 + Adebrelimab (NCT06618664)
- 2024-07-12Phase 3 first posted: National Cancer Institute (NCI), Durvalumab (NCT06498635)
- 2024-06-21Phase 3 first posted: AstraZeneca, Gemcitabine + Cisplatin (NCT06467357)
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Durvalumab (NCT04739800)
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Carboplatin (NCT02883062)
- 2024-03-19Results posted on the registry: AstraZeneca, Durvalumab / Tremelimumab Combination Therapy (NCT03837899)
- 2024-03-05Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Cisplatin (NCT03228537)
- 2024-02-28Phase 3 first posted: ETOP IBCSG Partners Foundation, Adjuvant durvalumab (NCT06284317)
- 2024-02-28Phase 3 first posted: Jazz Pharmaceuticals, Zanidatamab + Cisplatin (NCT06282575)
- 2024-01-18Phase 3 first posted: Amgen, Tarlatamab + Durvalumab (NCT06211036)
- 2023-12-12Results posted on the registry: Dana-Farber Cancer Institute, Palbociclib + Fulvestrant (NCT03147287)
- 2023-11-18Phase 3 first posted: Tokyo Medical and Dental University, Systemic therapy for 12 weeks after primary registration + Same systemic therapy after secondary registration (NCT06135714)
- 2023-11-01Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06112379)
- 2023-10-31Phase 3 first posted: AbbVie, Livmoniplimab + Budigalimab (NCT06109272)
- 2023-10-27Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT06103864)
- 2023-10-26Results posted on the registry: National Cancer Institute (NCI), Durvalumab + Vicineum (NCT03258593)
- 2023-09-28Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin (NCT06058377)
- 2023-06-18Results posted on the registry: AstraZeneca, Durvalumab + Tremelimumab (Regimen 1) (NCT03298451)
- 2023-06-01Phase 3 first posted: AstraZeneca, Durvalumab + Tremelimumab (NCT05883644)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision